Despite that first-line single agent ICB exhibited restricted activity in EGFR mutated NSCLC, the combination of immunotherapy and targeted agents has gained wide attention in both EGFR and ALK-positive NSCLC patients (12) Simultaneously, epigenetic marks led to the detection of potential cancer biomarkers for early screening, monitoring, and therapeutic methods of NSCLC (13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.